LianBio Q1 net loss $24M; mavacamten NDA accepted in China with priority review

LianBio

2023-Q1 EPS reported -$0.22 vs consensus -$0.28 ▲ beat (+21.6%)

Net loss of $24.0M in Q1 2023 vs $27.7M in Q1 2022; cash $286.6M at March 31, 2023.
Phase 3 EXPLORER-CN trial of mavacamten met primary endpoint in Chinese oHCM patients.
China NMPA accepted mavacamten NDA with priority review; approved in Macau in May 2023.
Pascal Qian promoted to Chief Commercial Officer to lead mavacamten launch preparations.
Cash runway projected through end of 2024; key milestones for TP-03, infigratinib, BBP-398.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LianBio reported the first quarter ended March 31, 2023 results: net income $24.0 million.

Period: the first quarter ended March 31, 2023
Net income: $24.0 million
Result: reported results

Exact text from the filing

Net loss was $24.0 million for the first quarter of 2023 compared to net loss of $27.7 million for the first quarter of 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.